Business Context and Reporting Period
Company: Astro-Med, Inc. (Note: Request metadata listed "Astronova, Inc.", but the filing is for Astro-Med, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: April 29, 2006
Business Overview: The company develops and manufactures data acquisition, analysis, and presentation systems. It operates through three segments: Test & Measurement (T&M), QuickLabel Systems (labeling solutions), and Grass Technologies (neurological instrumentation). Products are sold globally via direct sales and independent dealers.
Key Financial Metrics
| Metric | Q1 2006 | Q1 2005 |
|---|---|---|
| Net Sales | $15,641,524 | $14,193,266 |
| Gross Profit | $6,275,720 | $5,688,327 |
| Gross Margin | 40.1% | 40.1% |
| Operating Income | $712,218 | $515,576 |
| Net Income | $543,039 | $398,444 |
| Diluted EPS | $0.09 | $0.07 |
| Cash from Operations | $1,523,383 | $326,660 |
| Cash & Equivalents (End) | $4,454,526 | $3,539,314 |
| Total Current Assets | $41,541,622 | $39,662,066 |
| Total Current Liabilities | $9,149,516 | $8,439,627 |
| Debt | $0 (No borrowings on $3.5M line of credit) | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 10.2% year-over-year. The T&M segment drove this growth with a 44.0% increase, while QuickLabel and Grass Technologies grew 3.0% and 1.8%, respectively.
- Profitability: Operating income rose 38.1% to $712,000, and Net Income increased 36.3% to $543,000. This was achieved despite a 14.2% increase in G&A expenses and a 10.5% increase in R&D spending.
- Cash Flow: Operating cash flow improved significantly to $1.52 million from $327,000 in the prior year, attributed to better working capital management and a reduction in accounts receivable days (59 days vs. 60 days).
- Accounting Change: The company adopted SFAS No. 123(R) effective February 1, 2006, requiring the recognition of stock-based compensation expense. This reduced pre-tax income by approximately $100,000 for the quarter.
Guidance, Outlook, and Risks
- Outlook: Management expects to finance future needs through internal funds. A $3.5 million unsecured bank line of credit is available but currently unused. Stock-based compensation expense is estimated at $400,000 to $500,000 for the fiscal year ending January 31, 2007.
- Dividends: A quarterly dividend of $0.05 per share was declared and paid.
- Key Risks:
- Market Competition: Rapidly changing technology and new entrants in test & measurement, specialty printing, and neurophysiology markets.
- International Exposure: Approximately 30% of sales are international, exposing the company to currency fluctuations and foreign economic conditions.
- Supply Chain: Reliance on sole-source suppliers for certain components could lead to delays or price increases.
- Operational: Planned relocation of the Braintree, MA manufacturing facility in fiscal 2007 poses execution risks.
Investor Verification Checklist
- Segment Performance: Verify the sustainability of the 44% growth in the T&M segment, which was driven by the Ruggedized and Everest product lines.
- Working Capital: Confirm the continued improvement in Days Sales Outstanding (DSO) and monitor inventory levels, which increased 5.6% quarter-over-quarter.
- Accounting Impact: Assess the long-term impact of SFAS 123(R) adoption on future earnings, noting the $1.14 million in unrecognized compensation expense remaining.
- Liquidity: Review the utilization of the $3.5 million credit line and the company's ability to fund the planned facility relocation without external financing.
- Foreign Exchange: Monitor the impact of currency fluctuations on international sales, which had a $133,000 unfavorable impact in the quarter.